New hope for hard-to-treat blood cancers? early trial launches for targeted drug AZD9829
NCT ID NCT06179511
First seen Sep 30, 2025 · Last updated May 21, 2026 · Updated 32 times
Summary
This study tests a new drug called AZD9829 in people with blood cancers that have a specific marker (CD123) and have not responded to other treatments. The main goals are to find a safe dose and check for side effects. About 56 adults will take part, receiving the drug alone or with other medicines.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Duarte, California, 91010, United States
-
Research Site
St Louis, Missouri, 63110, United States
-
Research Site
New York, New York, 10021, United States
-
Research Site
Chapel Hill, North Carolina, 27514, United States
-
Research Site
Columbus, Ohio, 43210, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Milwaukee, Wisconsin, 53226, United States
-
Research Site
Heidelberg, 3084, Australia
-
Research Site
Melbourne, VIC 3000, Australia
-
Research Site
Tianjin, 300020, China
-
Research Site
Frankfurt, 60590, Germany
-
Research Site
Bologna, 40138, Italy
-
Research Site
Kashiwa, 227-8577, Japan
-
Research Site
Osaka, 545-8586, Japan
-
Research Site
Yoshida-gun, 910-1193, Japan
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Barcelona, 08035, Spain
-
Research Site
Salamanca, 37007, Spain
-
Research Site
Tainan, 704, Taiwan
-
Research Site
Taipei, 10002, Taiwan
-
Research Site
Manchester, M204BX, United Kingdom
Conditions
Explore the condition pages connected to this study.